Why it Matters

Prostate cancer is prevalent and deadly.

It represents the highest number of new cancer cases diagnosed annually and is the second-leading cause of cancer death among men.² Early detection and the ability to identify high-grade disease early are central to effective management.

Existing non-invasive options for prostate cancer risk assessment have meaningful limitations. miR Sentinel uses a urinary-exosome small-non-coding-RNA panel and a multi-class risk classifier as a complementary tool to support providers' decisions.

In its 432-patient independent test set, miR Sentinel correctly identified 97% (231/238) of patients with biopsy-confirmed prostate cancer as having Molecular Evidence of Prostate Cancer.¹

Download Order Form
for your provider

With less than 5% false positives, you will not be subject to unnecessary, painful and dangerous procedures.
With a higher true positive result than other tests, detecting the presence of prostate cancer is more likely
With a much higher true negative result than other tests, your chances of missing prostate cancer are much more rare
The miR Sentinel Prostate Cancer Test detects up to 93% of cancers that were missed by a standard biopsy, and only found during the following procedure in the current prostate cancer diagnosis, a MRI-guided prostate biopsy. (Site clinical study publication)
While the current standard of care (available screening methods) is Invasive, painful, and may cause significant side effects, it has only 68% accuracy. miR sentinel prostate cancer test, while pain-free with 0 side-effects provides confidence with over 90% accuracy.
Until now, the invasive screening process for prostate cancer did not provide a clear diagnosis for the different stages of cancer. The miR Scientific Sentinel pc Test provides one of four conclusive results that are critical for the continuum of care

Download Brochure

The miR Sentinel™ Prostate Cancer Test requires only a single, contact-free urine specimen.

Download Order Form
for your provider Download Brochure

No needles! You won’t have to give blood to get a diagnosis
No need for Digital Rectal Exams
It is a painless prostate cancer screening that doesn’t require biopsy needles in your sensitive, personal areas
By eliminating the need for biopsy, it eliminates risk of common side effects such as incontinence, impotence, infection, pain and bloody urine.

Download Brochure

miR Sentinel™ answers two of the most important questions:

1. Is there molecular evidence of prostate cancer?
‍
2. If so, how severe is the risk of aggressive disease?

Download Order Form
for your provider

For you it only means Pee in a cup. We’ll handle everything else.
It means No more blood tests.
No more prostate biopsies.
No more waiting for months for appointments.
No more dread, suspense or uncertainty.
With a simple urine test you get the answers you need without unnecessary disruption to your life.
If detected early, Prostate Cancer is almost 100% treatable. Our test provides quick results when time matters most.

Download Brochure

A single non-invasive test that supports both detection and multi-class risk stratification of prostate cancer at the molecular level.

Download Order Form
For your Provider

Our test allows you to get conclusive and accurate information that requires multiple tests in the current standard of care
Due to these unique capabilities, miR Sentinel Prostate Cancer Test can replace and outperform an array of multiple blood tests, invasive biopsies, and expensive imaging procedures with one simple pain-free step.
The test results accurately reflect 100% of the prostate at a molecular level, rather than a prostate cancer biopsy that has surgically removed less than 1% of the prostate to be manually reviewed.
The results will finally provide men with comprehensive information that will allow their doctors to create a tailored cancer monitoring, management, or treatment plan possible

Download Brochure

Why It Matters

Prostate cancer is prevalent and deadly.

It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among American men. Early detection and the ability to identify high grade disease early are key to effective disease management: If detected early, the survival rate is nearly 100%, but a late diagnosis drops survival to only 30%.

Unlike other cancers, a significant proportion of prostate cancers are indolent and are unlikely to need immediate treatment, and only a relatively small number of prostate cancer patients have an aggressive disease that requires intervention.

The challenge lies in effectively differentiating between the two, quickly, but until now, no effective, accurate and non-invasive tests have been developed for the early detection and grade classification of prostate cancer.

How to Get miR Sentinel^™

Available by prescription only.

Book an appointment with your medical provider and ask whether the miR Sentinel™ Prostate Cancer Test is appropriate for your situation, based on your clinical history and risk factors.

Telemedicine ordering anticipated Sept. 2026

STEP 1

Prescription

Book an appointment with your medical provider and request a prescription for the miR Sentinel™ Prostate Cancer Test.

Download Order Form
For your Doctor

STEP 2

Collection Kit

A specimen collection kit will be mailed to your home or provider's office.

STEP 3

Urine Specimen

Follow the instructions included in the collection kit and send your sample to the MiRNA Scientific laboratory using the included shipping label.

STEP 4

Results

Your provider will receive a comprehensive results report. Together you will discuss the meaning of the result and next steps.

References

1. Non-invasive Risk Assessment of Aggressive Prostate Cancer Using sncRNAs from Urinary Exosomes in a prospective, multi-center clinical study. [Manuscript in preparation]

2. American Cancer Society. Cancer Facts & Figures 2026. Atlanta: American Cancer Society; 2026. Accessed 20 March 2026. Available at https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/2026-cancer-facts-figures.html

3. Cheuck, L., et al. "Prostate Cancer Diagnosis and Staging." Medscape. 19 June 2023. Accessed 20 March 2026. https://emedicine.medscape.com/article/458011-overview.

4. Zhu, Kangmin et al. “Cancer incidence in the U.S. military population: comparison with rates from the SEER program.” Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 18,6 (2009): 1740-5. doi:10.1158/1055-9965.EPI-09-0041

5. US Department of Veterans Affairs. "Prostate Cancer Care at VA." Accessed 20 March 2026. https://www.cancer.va.gov/prostate.html

How to Get

Ask your provider if the miR Sentinel™ Prostate Cancer Test is right for you.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna
aliqua.

Download Order Form for your DoctorDownload Brochure

FAQ

How are the miR Sentinel™ Prostate Cancer Test results received?

The report will be securely delivered to the provider who ordered the test, either via secure fax or secure email.

Where is the miR Sentinel™ Prostate Cancer Test commercially available?

The miR Sentinel™ Prostate Cancer Test is commercially available in most U.S. states as well as Puerto Rico. The test is not currently available in New York.

What are the payment options for the miR Sentinel™ Prostate Cancer Test?

miR Sentinel has CPT PLA code 0424U and is listed on the 2026 Medicare Clinical Laboratory Fee Schedule. Broad coverage policies with private payers remain in build. MiRNA Scientific submits claims and pursues appeals on the patient's behalf. For Medicare beneficiaries: if a Medicare claim is denied, MiRNA Scientific does not bill the patient for any remaining balance. For other patients with out-of-pocket exposure, the miR Access patient-assistance program caps household out-of-pocket cost on a sliding scale based on income, with payment-over-time available. Almost all patients pay no more than approximately $250 for the test.

Is the miR Sentinel™ Prostate Cancer Test available in stores?

miR's Sentinel™ Prostate Cancer Test is currently only available through a healthcare provider. Please speak with your physician about possible testing options.

See All

Support

We're here to help! Visit our support center for FAQs and options to connect with a miR Sentinel expert directly.

Support Center

The miR Sentinel™
Prostate Cancer Test

miR Sentinel™ for Veterans

Why it Matters

In its 432-patient independent test set, miR Sentinel correctly identified 97% (231/238) of patients with biopsy-confirmed prostate cancer as having Molecular Evidence of Prostate Cancer.¹

The miR Sentinel™ Prostate Cancer Test requires only a single, contact-free urine specimen.

miR Sentinel™ answers two of the most important questions:

1. Is there molecular evidence of prostate cancer?
‍
2. If so, how severe is the risk of aggressive disease?

A single non-invasive test that supports both detection and multi-class risk stratification of prostate cancer at the molecular level.

Exceptional Sensitivity

Why It Matters

The challenge lies in effectively differentiating between the two, quickly, but until now, no effective, accurate and non-invasive tests have been developed for the early detection and grade classification of prostate cancer.

Now available in 45 US States and Puerto Rico